Compare Gilead Sciences, Inc. (GILD) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Mercadolibre Inc — how do they compare? Gilead Sciences, Inc. trades at $132.92 (market cap $163.51B), while Mercadolibre Inc trades at $1,851.16 (market cap $93.44B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| GILD | MELI | |
|---|---|---|
Market Cap | $163.51B | $93.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $2.51K |
52-Week Low | $108.22 | $1.55K |
Enterprise Value | $178.05B | $100.33B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
MercadoLibre (MELI) trades at $1,873.88, showing modest daily gains of 0.35% amid a generally bullish technical outlook. The stock exhibits strong fundamental growth with 2025 revenue reaching $28.89B and net income of $2.00B, though recent quarterly EPS results have missed analyst expectations. The company is strategically investing heavily in logistics, fulfillment, and fintech expansion, which is pressuring near-term margins but positioning for long-term market dominance in Latin America.
The investment outlook balances robust top-line growth and a dominant competitive position against margin compression from strategic investments and recent earnings misses. Wall Street sentiment remains overwhelmingly positive with a $2,230 consensus price target, but investors face risks from execution on growth investments, competitive pressures, and ongoing legal investigations highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
